The protein MIA (melanoma inhibitory activity) is highly expressed in malignant melanomas but not in melanocytes. Furthermore, expression of MIA correlates with tumor progression in vivo. Here, MIA-dependent changes of gene expression after long-term inhibition of MIA expression in the human melanoma cell line HMB2 were investigated. Primarily, we observed characteristic changes in cell morphology, and also found re-established cell-cell contacts in MIA-deficient cell clones grown in monolayer culture. Real-time reverse transcription-polymerase chain reaction (RT-PCR) showed a downregulation of N-cadherin expression and a reinduction of E-cadherin expression in the MIA-deficient cell clones. Further, both cancer cDNA array and protein arrays verified a marked downregulation of several other melanoma-associated genes (e.g. membrane-type 1 matrix metalloproteinase tissue-type plasminogen activator integrin b3, secreted protein acidic and rich in cysteins and fibronectin) in the MIA-deficient melanoma cells, confirmed by real-time RT-PCR and Western blotting. As all these molecules are associated with migration, the effect of MIA on migration of human primary melanocytes was analysed. In the presence of MIA, we observed enhanced migratory ability of melanocytic cells, induction of melanoma-associated genes as well as inhibition of apoptosis due to anoikis. These results suggest that expression of MIA promotes melanoma progression by inducing further melanoma-associated genes.
Introduction
Melanoma inhibitory activity (MIA) was cloned as a secreted protein from human melanoma cell lines (Blesch et al., 1994; van Groningen et al., 1995) . Later, it was shown that MIA is expressed in malignant melanomas and chondrosarcomas (Bosserhoff et al., 1996 (Bosserhoff et al., , 1999 . Today, increased serum levels of MIA serve as a reliable clinical marker to detect and monitor metastatic disease in patients with malignant melanomas (Bosserhoff et al., 1997; Stahlecker et al., 2000) , indicating an important role for them in tumor progression and metastasis.
For a deeper insight into the functional properties of MIA, multidimensional NMR (Stoll et al., 2000 and X-ray crystallography (Lougheed et al., 2001) were used to solve the three-dimensional structure of MIA. The corresponding data indicate that MIA defines a novel type of secreted protein, which adopts an SH3 domain-like fold in solution. Furthermore, nuclear magnetic resonance (NMR) spectra revealed that MIA interacts with peptides matching to type III human fibronectin repeats that are closely related to integrinbinding sites . These findings are supported by recent data showing that MIA shares significant structural homologies with the binding pockets of alpha4beta1 and alpha5beta1 integrins, suggesting that secreted MIA masks the respective integrin-binding epitopes on extracellular matrix molecules . These results are consistent with initial findings that MIA expression causes detachment of melanoma cells from the extracellular matrix or cell culture dishes, respectively , implicating a model, in which MIA regulates attachment/detachment of melanoma cells and promotes their migratory behavior.
This hypothesis is strengthened by in vivo experiments. In animal models, it was shown that MIA expression levels correlate closely with the capability of melanoma cells to form metastases (Guba et al., 2000; Bosserhoff et al., 2001) . In the study of Guba et al., A-mel 3 hamster melanoma cells were transfected with sense and antisense MIA cDNA and analysed subsequently for changes in their tumorigenic and metastatic potential. Enforced expression of MIA in A-mel 3 cells significantly increased their metastatic potential as compared with control or antisense transfected cells. In addition, MIA-overexpressing transfectants showed a higher rate of both tumor cell invasion and extravasation. Consistently, cell clones transfected with an antisense MIA cDNA expression plasmid revealed significantly reduced metastatic potential. The changes in metastatic behavior in correlation with the expression level of MIA provide evidence that upregulation of MIA during malignant transformation of melanocytic cells is causally involved in the acquisition of pathophysiologically relevant malignant characteristics. These results were further confirmed by a second study using B16 mouse melanoma cells in C57Bl6 mice. Here, B16 mouse melanoma cells secreting different amounts of MIA were generated by stable transfection . The capacity of these cell clones to form lung metastases in syngeneic C57Bl6 mice was strictly correlated to the level of MIA secretion.
Despite the extracellular effects of MIA on attachment of the cells by masking binding sites of the cellular matrix and therefore facilitating migration and metastasis of melanoma cells, endogenous effects on gene expression are also hypothesized.
In this study, we aimed to analyse the effect of MIA on expression of specific genes involved in the aggressive migration behavior of melanoma cells using an established model system of MIA-expressing melanoma cells and cell clones consistently lacking MIA expression. To verify MIA-induced changes of gene expression, primary human melanocytes were treated with MIA and further analysed with respect to expression of melanoma-relevant genes and altered migration behavior.
Results
The acquisition of an invasive and metastatic phenotype is a key event in tumor progression. Recent evidence revealed that the secreted protein MIA is highly expressed in malignant melanomas and associated with tumor progression in vivo. Here, we further investigated the role of MIA in the early process of tumor development by inhibiting MIA expression of the human melanoma cell line HMB2 consistently.
Establishing MIA-deficient melanoma cell clones
Long-term MIA-deficient melanoma cell clones were generated by stable transfection of the melanoma cell line HMB2 with an antisense MIA cDNA expression construct. Two cell clones completely lacking MIA expression (HMB2-5; HMB2-8) were chosen for further analysis. A cell clone expressing b-galactosidase (HMB2lacZ) was used as a mock control to verify the specificity of the MIA-deficient melanoma cell clones HMB2-5 and HMB2-8. Downregulation of MIA expression in HMB2-5 and HMB2-8 cell clones was confirmed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) (data not shown) and by determining the amount of MIA protein in the supernatant of the cells. HMB2lacZ showed MIA expression comparable to the parental cell line HMB2 (MIA expression of 1 million cells in 24 h: HMB2: 75 ng MIA/ml72.3 and HMB2lacZ: 79 ng MIA/ml74.8, compared to HMB2-5 and HMB2-8: 0 ng MIA/ml).
Changes in cell morphology
MIA-deficient cell clones revealed characteristic changes in cell morphology (Figure 1a) . Interestingly, in monolayer culture, HMB2-5 and HMB2-8 cells formed clusters, whereas HMB2 and HMB2lacZ cells showed the typical scattered growth pattern of melanoma cells. Further, HMB2-5 and HMB2-8 cells were significantly smaller than the parental melanoma cells (HMB2) (Figure 1b ). These findings implicated multiple alterations in gene expression induced by the long-term reduction of MIA in the MIA-deficient cell clones.
Comparison of mRNA expression pattern
To compare easily mRNA expression pattern of the cell clones, cDNA arrays resembling 588 cDNAs were performed using cDNA from HMB2 and HMB2-5 cells. Interestingly, the cancer cDNA array presented a marked downregulation of membrane-type 1 matrix metalloproteinase (MT1-MMP) (MMP14; membranetype 1 matrix metalloproteinase), t-PA (tissue-type plasminogen activator), integrin b3, SPARC (BM40, 'secreted protein acidic and rich in cysteins') and fibronectin mRNA in the MIA-deficient cell clone. All these genes are known to be associated with migration, metastasis and progression in melanoma and other kinds of cancer. Downregulation of the genes was confirmed by real-time RT-PCR analysing all four cell clones (HMB2, HMB2lacZ, HMB2-5, HMB2-8) as shown in Table 1 and Figure 2a and b. Expression levels of all genes analysed were strongly downregulated in the MIA-deficient cell clones. To verify the regulation of gene expression in MIA-deficient melanoma cells in other melanoma cell lines and species, additional cell clones previously generated from B16 mouse melanoma cells were analysed . Here, two cell clones were used: one cell clone showed reduction to 60% MIA expression compared to the original B16 cells (B16 60% MIA), the second cell clone only expressed 10% MIA (B16 10% MIA). Real-time PCR measuring mRNA expression of tPA, fibronectin, MT1-MMP, SPARC and integrin b3 revealed, in analogy to the HMB2 cell system, a markedly reduced expression in the MIA-deficient cell clones (Figure 2c) . Additionally, the results suggest a dose-dependent effect as the downregulation in the cell clones expressing still 60% MIA is smaller.
Comparison of protein expression pattern
To further confirm the findings on mRNA level, two different technologies were used to screen the protein expression pattern of HMB2 and MIA-deficient melanoma cells (HMB2-5 cell clone). Both antibody microarray (analysing expression of 380 proteins) and the 'Power Blot' method (analysing expression of 600 proteins) detected altered protein expression comparing the parental melanoma cell line to the HMB2-5 cell clone.
Downregulation of fibronectin (ratio HMB2-5/ HMB2: 0.342) and integrin b3 (ratio HMB2-5/HMB2: 0.58) protein expression in the MIA-deficient cell clone as shown in the cDNA cancer array was confirmed using the antibody microarray (t-PA, SPARC and MT1-MMP were not represented on this protein array). Furthermore, other genes associated with melanoma development and progression that were not represented on the cDNA array were found to be differentially expressed: L1 protein (ratio HMB2-5/HMB2: 0.025) and protein kinase C a (ratio HMB2-5/HMB2: 0.151) was also strongly downregulated in the MIA-deficient cell clone.
Using the 'Power Blot' method, downregulation in SPARC (ratio HMB2-5/HMB2: 0.22) and fibronectin (ratio HMB2-5/HMB2: 0.41) expression was observed reconfirming the results obtained by the cDNA array. Again, additional genes associated with melanoma development and progression were found to be differentially regulated comparing HMB2 to the MIAdeficient HMB2-5 cell clone. For example, the melanoma adhesion molecule MCAM (MUC18) was shown to only be expressed in the melanoma cells but not in the MIA-deficient cell clones. Additionally, N-cadherin, a known adhesion molecule only expressed in melanoma cells but not in melanocytes, is markedly downregulated in the MIA-deficient cell clone HMB2-5 (ratio HMB2-5/ HMB2: 0.12). Since neither MT1-MMP nor t-PA was included in both protein arrays (antibody array and Power Blot), expression levels of these proteins were The data are presented as Â fold change compared to HMB2/ HMB2lacZ set as 1 Alterations in expression of cell adhesion molecules
As we observed changes in cell morphology of the MIAdeficient cell clones as well as alterations in expression of melanoma-associated adhesion molecules (N-cadherin, MCAM), we further focused on the analysis of cell-cell adhesion. In melanoma, the switch from E-cadherin expression to N-cadherin expression presents an early and essential step for transition of melanocytes to migrating melanoma cells. Therefore, we analysed the expression pattern of N-and E-cadherin in the parental cell line HMB2 and the MIA-deficient cell clones. Realtime RT-PCR demonstrated a downregulation of Ncadherin expression in the MIA-deficient cell clones as shown on protein level by Power Blot technology ( Figure 4 ). Vice versa, strong upregulation of E-cadherin mRNA expression was seen in HMB2-5 and -8. Western blot analysis was performed to confirm an induction of E-cadherin expression in the MIA-deficient cell clones ( Figure 3 ) as E-cadherin was neither represented on the antibody array nor by the Power Blot analysis.
Role of MIA in melanocytic migration
Comparing the melanoma cell line HMB2 and MIAdeficient cell clones, several genes known to be associated with migration in malignant melanoma, including molecules of the cadherin system, were shown to be regulated by MIA. It is well known that loss of Ecadherin expression and subsequent loss of growth control of melanocytes mediated by keratinocytes is a very important and early step in melanoma progression. Therefore, we speculated that the extracellular presence of MIA might have an influence on the migratory potential of melanocytic cells. Given that MIA is a secreted protein, primary human melanocytes were treated with recombinant MIA (rMIA, 100 ng/ml), and the effect on migration and colony-forming abilities was monitored. Migration behavior of melanocytes with and without MIA treatment was analysed in the Boyden Chamber model ( Figure 5 ). Nonstimulated melanocytes showed almost no migratory capacity whereas migration was significantly induced by treatment with rMIA (100ng/ml).
To answer the question as to whether the observed changes in migration behavior of primary human melanocytes after MIA treatment were due to altered expression of the same genes found downregulated in the MIA-deficient melanoma cell clones, we investigated whether MIA treatment induced an upregulation of t- (Table 2 ). This analysis clearly revealed that in MIA-treated primary human melanocytes, all five genes important for migratory processes were strongly upregulated. Usually, in the epidermis of the human skin, melanocytes are located solitary on the basement membrane and detachment of the cells would result in induction of apoptosis due to anoikis. To analyse whether induction of migration of human primary melanocytes via MIA treatment was accomplished by suppression of anoikis/apoptosis, colony-forming assays were performed (Figure 6 ). Compared to untreated human melanocytes, attachment-independent growth and colony-forming was observed by MIA-treated human melanocytes implicating that induction of apoptosis was inhibited.
PHM
Evaluation of cDNA array, Power Blot and/or antibody array data comparing the melanoma cell line HMB2 and MIA-deficient cell clones revealed no changes in expression of apoptosis-related genes like bcl-2, bax and bcl-x (data not shown), but showed a strong induction of Apaf-1 expression in the MIAdeficient cell clones (Figure 7) . It is well known that, in contrast to other tumor types, in malignant melanoma loss of apoptosis protease activating factor 1 (Apaf-1) but not the presence of mutated p53 is crucial to avoid apoptosis (Soengas et al., 2001) . Further, it was described recently that E2F transcription factor 1 (E2F-1) is an upstream regulator of Apaf-1 (Furukawa et al., 2002) . Consistent with upregulated Apaf-1, 'Power Blot' analysis revealed that (E2F-1) expression was also upregulated in the MIA-deficient cell clone HMB2-5 (Figure 7) .
Additionally, we analysed Apaf-1 expression in melanocytes treated with MIA for 24 h by quantitative real-time PCR. In MIA-treated human melanocytes, we detected a 2.4-fold downregulation of Apaf-1 expression (70.37) confirming MIA-induced inhibition of apoptotic mechanisms to promote enhanced migratory abilities.
Discussion
MIA is a protein known to play an important role in melanoma metastasis (Bosserhoff and Buettner, 2002) . As there is evidence that MIA is expressed in some nevi and in all small primary melanoma analysed, but not in without MIA treatment plus 100ng/ml MIA Figure 6 Influence of MIA treatment on colony formation of primary human melanocytes. Colony-forming assays were performed using primary human melanocytes (PHM). Treatment with MIA was performed by addition of 100 ng/ml MIA to the cells. Representative pictures (two for each condition) were taken after 14 days of cultivation (magnification 10-fold) The data are presented as Â fold change compared to untreated melanocytes set as 1
Functional role of MIA I Poser et al normal human epidermal melanocytes (Bosserhoff and Buettner, 1999) , we speculated a function of MIA in early melanoma development. To determine endogenous effects of MIA clearly, we generated melanoma cells completely and consistently lacking MIA expression by stable antisense MIA cDNA transfection. These cells were analysed for differences compared to the parental cell line on mRNA and protein level by cDNA arrays, antibody arrays and high throughput Western blot analysis (Power Blot). Interestingly, several genes known to be important and strongly overexpressed in malignant melanoma were shown to be downregulated in MIA-deficient cell clones: t-PA, SPARC (BM40, osteonectin), MT1-MMP, integrin b3 and fibronectin. A large body of evidence suggests a role for t-PA (Saksela et al., 1984; Meissauer et al., 1991; Alizadeh et al., 1995; de Vries et al., 1996) , SPARC (Ledda et al., 1997a, b; Massi et al., 1999; Sturm et al., 2002) , MT1-MMP (Hofmann et al., 2000a, b; Seftor et al., 2001; Krengel et al., 2002; Sounni et al., 2002; Iida et al., 2004) , integrin b3 (Nip et al., 1992; Natali et al., 1995; Van Belle et al., 1999; Felding-Habermann et al., 2002; Sturm et al., 2002) and fibronectin (Wollina et al., 1991; Natali et al., 1995) in migration, invasion and metastatic spread of melanoma cells. Since these proteins are directly or indirectly involved in matrix degradation (t-PA, MT1-MMP), in the transition of melanomas being in radial growth phase to a vertical growth phase (induction of SPARC by integrin b3) and enforced cell proliferation (fibronectin), induction of gene expression by MIA could account for several abilities that melanoma cells harbor during tumor development and progression.
Additionally, further genes associated with melanoma development and progression were identified as differentially expressed as MCAM/ MUC18, L1 protein and protein kinase C a (Hsu et al., 2002) .
Interestingly, in the presence of MIA, primary human melanocytes showed upregulation of all five analysed migration-relevant genes: t-PA, fibronectin, MT1-MMP, integrin b3 and SPARC.
Importantly, not only genes directly linked to migration of melanoma cells were displayed to be regulated by changes in MIA expression but also proteins of the cadherin family. It is known that the switch from E-to Ncadherin expression is an early and important step in melanoma development enabling the cells to escape the growth control mediated by keratinocytes (Li et al., 2001) .
Here, it was clearly shown that MIA-deficient melanoma cells re-express E-cadherin but lose N-cadherin expression. Further experiments need to address the question of whether the switch in cadherin expression is primarily or secondarily induced by the presence of MIA. For nevi, it was recently stated that loss of E-cadherin expression is controlled by the microenvironment (Krengel et al., 2004) . It is possible that MIA may not be the leading impulse but the maintaining factor of N-cadherin expression in melanoma cells.
Another aspect of enhanced migratory abilities of melanoma cells and possibly of melanocytes in a temporary manner is protection from apoptosis due to reduced cell-cell-and cell-matrix contacts (anoikis). Consequently, we analysed genes such relevant for control of apoptosis. In several apoptosis-related genes such as bcl-2, bax or bcl-x, no significant changes in expression were determined. In accordance, Selzer et al. (1998) could show that these genes such are equally expressed comparing melanocytes and melanoma. Recently, several groups presented Apaf-1 as the main regulator of apoptosis in malignant melanoma (Soengas et al., 2001; Bowen et al., 2003; Paggi et al., 2003) . Furthermore, Apaf-1 was shown to be regulated by the transcription factor E2F-1 (Furukawa et al., 2002) . In our analysis, we found Apaf-1 and E2F-1 to be upregulated in the MIA-deficient melanoma cells HMB2-5. Further, enhanced colony-forming abilities of MIA-treated human melanocytes in soft agar accomplished by inhibition of apoptosis (due to upregulation of Apaf-1) implicates complex interactions of signaling pathways and alteration of gene expression.
Extended studies have to clarify whether melanocytes do express MIA during embryogenesis, nevi formation and/or wound healing. It is obvious that well-controlled expression and secretion of MIA by melanocytes coupled with inhibition of apoptosis could serve as a proliferation stimulus and would enable the cells to temporarily adhesion-independent growth.
In summary, we could clearly show that expression of MIA by malignant melanoma regulates expression of a variety of several melanoma-associated genes, being mainly associated to migration. Furthermore, our data implicate that MIA either directly or indirectly induces the switch from E-to N-cadherin expression. Since this event constitutes a crucial basis for malignant progres- sion, the escape of growth control, MIA expression may be an early event in melanoma development. The role of MIA in inducing migration and migration-associated genes was also demonstrated in primary human melanocytes. These cells required migratory abilities and exhibited reduced expression of apoptotic genes after treatment with MIA. We speculate that under physiological conditions (wound healing or embryogenesis), melanocytes are able to induce a precisely restricted expression of MIA. The exact mechanisms regulating defined MIA expression in melanocytes as well as MIA's precise function in regulating gene expression in melanoma cells still remain to be revealed and are subject to further investigations.
Materials and methods

Cell lines and cell culture conditions
The melanoma cell lines HMB2 and B16 have been described in detail previously (Jacob et al., 1998; Bosserhoff et al., 2001) . HMB2 was derived from a metastasis of malignant melanomas. For tissue culture, the cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with penicillin (400 U/ml), streptomycin (50 mg/ml), L-glutamine (300 mg/ml) and 10% fetal calf serum serum (FCS; Sigma, Deisenhofen, Germany) and splitted 1 : 5 every 3 days. A panel of HMB2 cell clones varying with respect to MIA expression were established by stable transfection with MIA-antisense expression plasmids, controlled by a CMV-promoter and cotransfected with pCDNA3 (Invitrogen NV Leek, Holland), containing the selectable marker for neomycin resistance. Controls received pCDNA3 plus pCMVb, a plasmid for expression of b-galactosidase (Invitrogen). Transfections were performed using the lipofectamin (Gibco, Eggenstein, Germany) method. At 1 day after transfection, cells were placed in selection medium containing 50 mg/ml G418 (Sigma Aldrich Deisenhofen, Germany). After 25 days of selection, individual G418-resistant colonies were subcloned. The amount of MIA expression in these clones was determined by measuring MIA in the 24 h tissue culture supernatants using a quantitative MIA specific enzyme-linked immunosorbant assay (ELISA) (Roche, Mannheim, Germany).
Primary human melanocytes (PHM) derived from normal skin were cultivated in melanocyte medium, melanocyte growth medium no. 3 (MGM-3) (Gibco) under a humified atmosphere of 5% CO 2 at 371C. Cells were used in passages 1-3 and not later than 3 days after trypsinization. Cells were detached for subcultivation or assay with 0.05% trypsin, 0.04% ethylenediaminetetraacetic acid (EDTA) in phosphatebuffered saline (PBS).
For measuring MIA expression, a commercially available MIA-ELISA (Roche) was used according to the manufacturer's instruction.
Measurement of the cell size was performed using a Carl Zeiss microscope and the K300 software (Carl Zeiss Vision GmbH, Germany). For each cell clone the area of 20 cells was determined and statistics were calculated.
cDNA expression array
Commercially available cDNA expression arrays (Atlas human cancer cDNA expression array, Clontech, Palo Alto, USA) were used to compare the gene expression of the two cell clones HMB2 and HMB2-5. Arrays were screened according to the manufacturer's protocol. Total RNA (10 mg) from each cell clone was radiolabeled using MMLV reverse transcriptase and a specific primer set (10 Â CDS Primer Mix) supplied by the manufacturer. Probes were purified on Chroma Spin-200 columns and the specific radioactivity was then measured. Hybridization was performed overnight at 681C in a solution of ExpressHyb, sheared salmon testes DNA and labeled cDNA (final concentration 0.5-1 Â 10 6 c.p.m./ml). Blots were washed three times for 20 min in 2 Â SSC, 1% SDS at 681C, followed by two additional washes for 20 min in 0.1x SSC, 0.5% SDS at 681C. The damp membrane was wrapped immediately and exposed both to an X-ray film and to a Phospho-imager screen, respectively. For interpretation of the results, two different software programs were used (Molecular Devices, Clontech).
Antibody microarray
To analyse proteins regulated by MIA, we used a fluorescencebased antibody mircoarray (Clontech) in which a solid-phase antibody captures fluorescently labeled antigen. The array was performed according to the manufacturer's instructions.
Briefly, total protein was extracted from the melanoma cell line HMB2 expressing strong levels of MIA and HMB2-5 cell clones with reduced MIA level by multiple freezing and thawing cycles and resuspended in labeling buffer. Each protein sample (500 mg) was labeled with Cy3 and Cy5, respectively, to produce four samples. After removing unbound dye, one microarray slide was incubated with 25 mg total protein of combined HMB2-Cy3 and HMB2-5-Cy5 and the other slide with HMB2-Cy5 and HMB2-5-Cy3 to normalize labeling efficiency. For example, if Cy5 reacts more efficiently with the protein targets than Cy3 does, the results will be biased in favor of the sample labeled with Cy5. With this sampling method these differences are eliminated. Therefore, after scanning both slides with a Chipreader (ScanArray 4000, Packard BioChip Technology, USA), the internally normalized ratio (INR) was calculated (square root of division of ratio1 by ratio2).
Prelabeled bovine serum albumin (BSA) spots with Cy3 and Cy5 served as orientation markers on the slide, while other unlabeled spots served as negative control.
'Power Blot' protein array
To analyse protein expression pattern comparing HMB2 to the MIA-deficient cell clones, HMB2-5, Power Blot analysis was performed by BD Clontech. Protein extracts of the cell lines were prepared following the manufacturer's instruction and analysed in triplicate using 600 antibodies via Western blot technology. Evaluation was performed semiquantitatively by densitometrically evaluation of each signal.
Quantitative RT-PCR
To quantify precisely the expression of cDNAs, the real-time PCR the LightCycler system (Roche) was used. For PCR, 1-3 ml cDNA preparation, 0.5-2.4 ml 25 mM MgCl 2 , 0.5 mM of forward and reverse primer (Atlas RT-PCR Primer, Clontech) and 2 ml of SybrGreen LightCycler Mix in a total of 20 ml were applied. The following PCR program was performed: 60 s 951C (initial denaturation); 201C/s temperature transition rate up to 951C for 15 s, 10 s 58-681C, 22 s 721C, 10 s 821C including single acquisition mode, repeated for 40 times (amplification). MgCl 2 concentration and annealing temperature were optimized for each primer set. The PCR reaction was evaluated by melting curve analysis following the manufacturer's instructions and checking the PCR products on 1.8% agarose gels. Each quantitative PCR was performed at least in duplicate for two sets of RNA preparations. RNA was isolated using a Mini RNA Isolation Kit (Qiagen, Hilden, Germany).
Western blotting
Cells (3 Â 10 6
